Back to Search
Start Over
Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.
- Source :
-
Pigment Cell & Melanoma Research . Jan2018, Vol. 31 Issue 1, p73-81. 9p. - Publication Year :
- 2018
-
Abstract
- To determine the feasibility of liquid biopsy for monitoring of patients with advanced melanoma, cell-free DNA was extracted from plasma for 25 Stage III/IV patients, most (84.0%) having received previous therapy. DNA concentrations ranged from 0.6 to 390.0 ng/ml (median = 7.8 ng/ml) and were positively correlated with tumor burden as measured by imaging (Spearman rho = 0.5435, p = .0363). Using ultra-deep sequencing for a 61-gene panel, one or more mutations were detected in 12 of 25 samples (48.0%), and this proportion did not vary significantly for patients on or off therapy at the time of blood draw (52.9% and 37.5% respectively; p = .673). Sixteen mutations were detected in eight different genes, with the most frequent mutations detected in BRAF, NRAS, and KIT. Allele fractions ranged from 1.1% to 63.2% (median = 29.1%). Among patients with tissue next-generation sequencing, nine of 11 plasma mutations were also detected in matched tissue, for a concordance of 81.8%. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17551471
- Volume :
- 31
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Pigment Cell & Melanoma Research
- Publication Type :
- Academic Journal
- Accession number :
- 127026485
- Full Text :
- https://doi.org/10.1111/pcmr.12623